Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. They do not cure psychosis but help in controlling symptoms such as hallucinations, and delusions, among others.

The global Atypical Antipsychotic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Atypical Antipsychotic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Atypical Antipsychotic Drugs.

Report Scope

The Atypical Antipsychotic Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Atypical Antipsychotic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Atypical Antipsychotic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Atypical Antipsychotic Drugs Market Report

Report Metric	Details
Report Name	Atypical Antipsychotic Drugs Market
CAGR	5%
Segment by Type	Risperidone Olanzapine Quetiapine Ziprasidone Others
Segment by Application	Bipolar I Disorder Schizophrenia Schizoaffective Disorder Major Depressive Disorder (MDD)
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novartis AG, Cardinal Health, Johnson and Johnson, Allergan, Sanis Health, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries, Eil Lilly and Company, AstraZeneca, Sumitomo Dainippon Pharma, Qilu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Atypical Antipsychotic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Atypical Antipsychotic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Atypical Antipsychotic Drugs Market report?

Ans: The main players in the Atypical Antipsychotic Drugs Market are Novartis AG, Cardinal Health, Johnson and Johnson, Allergan, Sanis Health, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries, Eil Lilly and Company, AstraZeneca, Sumitomo Dainippon Pharma, Qilu Pharmaceutical

What are the Application segmentation covered in the Atypical Antipsychotic Drugs Market report?

Ans: The Applications covered in the Atypical Antipsychotic Drugs Market report are Bipolar I Disorder, Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder (MDD)

What are the Type segmentation covered in the Atypical Antipsychotic Drugs Market report?

Ans: The Types covered in the Atypical Antipsychotic Drugs Market report are Risperidone, Olanzapine, Quetiapine, Ziprasidone, Others

1 Atypical Antipsychotic Drugs Market Overview

1.1 Product Overview and Scope of Atypical Antipsychotic Drugs

1.2 Atypical Antipsychotic Drugs Segment by Type

1.2.1 Global Atypical Antipsychotic Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Risperidone

1.2.3 Olanzapine

1.2.4 Quetiapine

1.2.5 Ziprasidone

1.2.6 Others

1.3 Atypical Antipsychotic Drugs Segment by Application

1.3.1 Global Atypical Antipsychotic Drugs Market Value by Application: (2024-2030)

1.3.2 Bipolar I Disorder

1.3.3 Schizophrenia

1.3.4 Schizoaffective Disorder

1.3.5 Major Depressive Disorder (MDD)

1.4 Global Atypical Antipsychotic Drugs Market Size Estimates and Forecasts

1.4.1 Global Atypical Antipsychotic Drugs Revenue 2019-2030

1.4.2 Global Atypical Antipsychotic Drugs Sales 2019-2030

1.4.3 Global Atypical Antipsychotic Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Atypical Antipsychotic Drugs Market Competition by Manufacturers

2.1 Global Atypical Antipsychotic Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Atypical Antipsychotic Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Atypical Antipsychotic Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Atypical Antipsychotic Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Atypical Antipsychotic Drugs, Product Type & Application

2.7 Atypical Antipsychotic Drugs Market Competitive Situation and Trends

2.7.1 Atypical Antipsychotic Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Atypical Antipsychotic Drugs Players Market Share by Revenue

2.7.3 Global Atypical Antipsychotic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Atypical Antipsychotic Drugs Retrospective Market Scenario by Region

3.1 Global Atypical Antipsychotic Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Atypical Antipsychotic Drugs Global Atypical Antipsychotic Drugs Sales by Region: 2019-2030

3.2.1 Global Atypical Antipsychotic Drugs Sales by Region: 2019-2024

3.2.2 Global Atypical Antipsychotic Drugs Sales by Region: 2025-2030

3.3 Global Atypical Antipsychotic Drugs Global Atypical Antipsychotic Drugs Revenue by Region: 2019-2030

3.3.1 Global Atypical Antipsychotic Drugs Revenue by Region: 2019-2024

3.3.2 Global Atypical Antipsychotic Drugs Revenue by Region: 2025-2030

3.4 North America Atypical Antipsychotic Drugs Market Facts & Figures by Country

3.4.1 North America Atypical Antipsychotic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Atypical Antipsychotic Drugs Sales by Country (2019-2030)

3.4.3 North America Atypical Antipsychotic Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Atypical Antipsychotic Drugs Market Facts & Figures by Country

3.5.1 Europe Atypical Antipsychotic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Atypical Antipsychotic Drugs Sales by Country (2019-2030)

3.5.3 Europe Atypical Antipsychotic Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Atypical Antipsychotic Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Atypical Antipsychotic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Atypical Antipsychotic Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Atypical Antipsychotic Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Atypical Antipsychotic Drugs Market Facts & Figures by Country

3.7.1 Latin America Atypical Antipsychotic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Atypical Antipsychotic Drugs Sales by Country (2019-2030)

3.7.3 Latin America Atypical Antipsychotic Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Atypical Antipsychotic Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Atypical Antipsychotic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Atypical Antipsychotic Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Atypical Antipsychotic Drugs Sales by Type (2019-2030)

4.1.1 Global Atypical Antipsychotic Drugs Sales by Type (2019-2024)

4.1.2 Global Atypical Antipsychotic Drugs Sales by Type (2025-2030)

4.1.3 Global Atypical Antipsychotic Drugs Sales Market Share by Type (2019-2030)

4.2 Global Atypical Antipsychotic Drugs Revenue by Type (2019-2030)

4.2.1 Global Atypical Antipsychotic Drugs Revenue by Type (2019-2024)

4.2.2 Global Atypical Antipsychotic Drugs Revenue by Type (2025-2030)

4.2.3 Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Atypical Antipsychotic Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Atypical Antipsychotic Drugs Sales by Application (2019-2030)

5.1.1 Global Atypical Antipsychotic Drugs Sales by Application (2019-2024)

5.1.2 Global Atypical Antipsychotic Drugs Sales by Application (2025-2030)

5.1.3 Global Atypical Antipsychotic Drugs Sales Market Share by Application (2019-2030)

5.2 Global Atypical Antipsychotic Drugs Revenue by Application (2019-2030)

5.2.1 Global Atypical Antipsychotic Drugs Revenue by Application (2019-2024)

5.2.2 Global Atypical Antipsychotic Drugs Revenue by Application (2025-2030)

5.2.3 Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Atypical Antipsychotic Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novartis AG

6.1.1 Novartis AG Corporation Information

6.1.2 Novartis AG Description and Business Overview

6.1.3 Novartis AG Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novartis AG Atypical Antipsychotic Drugs Product Portfolio

6.1.5 Novartis AG Recent Developments/Updates

6.2 Cardinal Health

6.2.1 Cardinal Health Corporation Information

6.2.2 Cardinal Health Description and Business Overview

6.2.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Cardinal Health Atypical Antipsychotic Drugs Product Portfolio

6.2.5 Cardinal Health Recent Developments/Updates

6.3 Johnson and Johnson

6.3.1 Johnson and Johnson Corporation Information

6.3.2 Johnson and Johnson Description and Business Overview

6.3.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio

6.3.5 Johnson and Johnson Recent Developments/Updates

6.4 Allergan

6.4.1 Allergan Corporation Information

6.4.2 Allergan Description and Business Overview

6.4.3 Allergan Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Allergan Atypical Antipsychotic Drugs Product Portfolio

6.4.5 Allergan Recent Developments/Updates

6.5 Sanis Health

6.5.1 Sanis Health Corporation Information

6.5.2 Sanis Health Description and Business Overview

6.5.3 Sanis Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Sanis Health Atypical Antipsychotic Drugs Product Portfolio

6.5.5 Sanis Health Recent Developments/Updates

6.6 Pfizer

6.6.1 Pfizer Corporation Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Pfizer Atypical Antipsychotic Drugs Product Portfolio

6.6.5 Pfizer Recent Developments/Updates

6.7 GlaxoSmithKline

6.6.1 GlaxoSmithKline Corporation Information

6.6.2 GlaxoSmithKline Description and Business Overview

6.6.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio

6.7.5 GlaxoSmithKline Recent Developments/Updates

6.8 Bristol-Myers Squibb Company

6.8.1 Bristol-Myers Squibb Company Corporation Information

6.8.2 Bristol-Myers Squibb Company Description and Business Overview

6.8.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio

6.8.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.9 Sun Pharmaceutical Industries

6.9.1 Sun Pharmaceutical Industries Corporation Information

6.9.2 Sun Pharmaceutical Industries Description and Business Overview

6.9.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio

6.9.5 Sun Pharmaceutical Industries Recent Developments/Updates

6.10 Eil Lilly and Company

6.10.1 Eil Lilly and Company Corporation Information

6.10.2 Eil Lilly and Company Description and Business Overview

6.10.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio

6.10.5 Eil Lilly and Company Recent Developments/Updates

6.11 AstraZeneca

6.11.1 AstraZeneca Corporation Information

6.11.2 AstraZeneca Atypical Antipsychotic Drugs Description and Business Overview

6.11.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 AstraZeneca Atypical Antipsychotic Drugs Product Portfolio

6.11.5 AstraZeneca Recent Developments/Updates

6.12 Sumitomo Dainippon Pharma

6.12.1 Sumitomo Dainippon Pharma Corporation Information

6.12.2 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Description and Business Overview

6.12.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio

6.12.5 Sumitomo Dainippon Pharma Recent Developments/Updates

6.13 Qilu Pharmaceutical

6.13.1 Qilu Pharmaceutical Corporation Information

6.13.2 Qilu Pharmaceutical Atypical Antipsychotic Drugs Description and Business Overview

6.13.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio

6.13.5 Qilu Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Atypical Antipsychotic Drugs Industry Chain Analysis

7.2 Atypical Antipsychotic Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Atypical Antipsychotic Drugs Production Mode & Process

7.4 Atypical Antipsychotic Drugs Sales and Marketing

7.4.1 Atypical Antipsychotic Drugs Sales Channels

7.4.2 Atypical Antipsychotic Drugs Distributors

7.5 Atypical Antipsychotic Drugs Customers

8 Atypical Antipsychotic Drugs Market Dynamics

8.1 Atypical Antipsychotic Drugs Industry Trends

8.2 Atypical Antipsychotic Drugs Market Drivers

8.3 Atypical Antipsychotic Drugs Market Challenges

8.4 Atypical Antipsychotic Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Eil Lilly and Company

Astrazeneca plc

Sumitomo Dainippon Pharma

Qilu Pharmaceutical

Company

Bristol Myers Squibb Company

Sun Pharmaceutical Industries

List of Tables

Table 1. Global Atypical Antipsychotic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Atypical Antipsychotic Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Atypical Antipsychotic Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Atypical Antipsychotic Drugs Sales (Units) of Key Manufacturers (2019-2024)

Table 5. Global Atypical Antipsychotic Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Atypical Antipsychotic Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Atypical Antipsychotic Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Atypical Antipsychotic Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Atypical Antipsychotic Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Atypical Antipsychotic Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Atypical Antipsychotic Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Atypical Antipsychotic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Atypical Antipsychotic Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Atypical Antipsychotic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Atypical Antipsychotic Drugs Sales by Region (2019-2024) & (Units)

Table 18. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Atypical Antipsychotic Drugs Sales by Region (2025-2030) & (Units)

Table 20. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Atypical Antipsychotic Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Atypical Antipsychotic Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Atypical Antipsychotic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Atypical Antipsychotic Drugs Sales by Country (2019-2024) & (Units)

Table 27. North America Atypical Antipsychotic Drugs Sales by Country (2025-2030) & (Units)

Table 28. North America Atypical Antipsychotic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Atypical Antipsychotic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Atypical Antipsychotic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Atypical Antipsychotic Drugs Sales by Country (2019-2024) & (Units)

Table 32. Europe Atypical Antipsychotic Drugs Sales by Country (2025-2030) & (Units)

Table 33. Europe Atypical Antipsychotic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Atypical Antipsychotic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Atypical Antipsychotic Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Atypical Antipsychotic Drugs Sales by Region (2019-2024) & (Units)

Table 37. Asia Pacific Atypical Antipsychotic Drugs Sales by Region (2025-2030) & (Units)

Table 38. Asia Pacific Atypical Antipsychotic Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Atypical Antipsychotic Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Atypical Antipsychotic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Atypical Antipsychotic Drugs Sales by Country (2019-2024) & (Units)

Table 42. Latin America Atypical Antipsychotic Drugs Sales by Country (2025-2030) & (Units)

Table 43. Latin America Atypical Antipsychotic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Atypical Antipsychotic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Atypical Antipsychotic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Atypical Antipsychotic Drugs Sales by Country (2019-2024) & (Units)

Table 47. Middle East & Africa Atypical Antipsychotic Drugs Sales by Country (2025-2030) & (Units)

Table 48. Middle East & Africa Atypical Antipsychotic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Atypical Antipsychotic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Atypical Antipsychotic Drugs Sales (Units) by Type (2019-2024)

Table 51. Global Atypical Antipsychotic Drugs Sales (Units) by Type (2025-2030)

Table 52. Global Atypical Antipsychotic Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Atypical Antipsychotic Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Type (2019-2024)

Table 59. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Type (2025-2030)

Table 60. Global Atypical Antipsychotic Drugs Sales (Units) by Application (2019-2024)

Table 61. Global Atypical Antipsychotic Drugs Sales (Units) by Application (2025-2030)

Table 62. Global Atypical Antipsychotic Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Atypical Antipsychotic Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Application (2019-2024)

Table 69. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Application (2025-2030)

Table 70. Novartis AG Corporation Information

Table 71. Novartis AG Description and Business Overview

Table 72. Novartis AG Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 73. Novartis AG Atypical Antipsychotic Drugs Product

Table 74. Novartis AG Recent Developments/Updates

Table 75. Cardinal Health Corporation Information

Table 76. Cardinal Health Description and Business Overview

Table 77. Cardinal Health Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 78. Cardinal Health Atypical Antipsychotic Drugs Product

Table 79. Cardinal Health Recent Developments/Updates

Table 80. Johnson and Johnson Corporation Information

Table 81. Johnson and Johnson Description and Business Overview

Table 82. Johnson and Johnson Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 83. Johnson and Johnson Atypical Antipsychotic Drugs Product

Table 84. Johnson and Johnson Recent Developments/Updates

Table 85. Allergan Corporation Information

Table 86. Allergan Description and Business Overview

Table 87. Allergan Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 88. Allergan Atypical Antipsychotic Drugs Product

Table 89. Allergan Recent Developments/Updates

Table 90. Sanis Health Corporation Information

Table 91. Sanis Health Description and Business Overview

Table 92. Sanis Health Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 93. Sanis Health Atypical Antipsychotic Drugs Product

Table 94. Sanis Health Recent Developments/Updates

Table 95. Pfizer Corporation Information

Table 96. Pfizer Description and Business Overview

Table 97. Pfizer Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 98. Pfizer Atypical Antipsychotic Drugs Product

Table 99. Pfizer Recent Developments/Updates

Table 100. GlaxoSmithKline Corporation Information

Table 101. GlaxoSmithKline Description and Business Overview

Table 102. GlaxoSmithKline Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 103. GlaxoSmithKline Atypical Antipsychotic Drugs Product

Table 104. GlaxoSmithKline Recent Developments/Updates

Table 105. Bristol-Myers Squibb Company Corporation Information

Table 106. Bristol-Myers Squibb Company Description and Business Overview

Table 107. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 108. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product

Table 109. Bristol-Myers Squibb Company Recent Developments/Updates

Table 110. Sun Pharmaceutical Industries Corporation Information

Table 111. Sun Pharmaceutical Industries Description and Business Overview

Table 112. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 113. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product

Table 114. Sun Pharmaceutical Industries Recent Developments/Updates

Table 115. Eil Lilly and Company Corporation Information

Table 116. Eil Lilly and Company Description and Business Overview

Table 117. Eil Lilly and Company Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 118. Eil Lilly and Company Atypical Antipsychotic Drugs Product

Table 119. Eil Lilly and Company Recent Developments/Updates

Table 120. AstraZeneca Corporation Information

Table 121. AstraZeneca Description and Business Overview

Table 122. AstraZeneca Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 123. AstraZeneca Atypical Antipsychotic Drugs Product

Table 124. AstraZeneca Recent Developments/Updates

Table 125. Sumitomo Dainippon Pharma Corporation Information

Table 126. Sumitomo Dainippon Pharma Description and Business Overview

Table 127. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 128. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product

Table 129. Sumitomo Dainippon Pharma Recent Developments/Updates

Table 130. Qilu Pharmaceutical Corporation Information

Table 131. Qilu Pharmaceutical Description and Business Overview

Table 132. Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 133. Qilu Pharmaceutical Atypical Antipsychotic Drugs Product

Table 134. Qilu Pharmaceutical Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Atypical Antipsychotic Drugs Distributors List

Table 138. Atypical Antipsychotic Drugs Customers List

Table 139. Atypical Antipsychotic Drugs Market Trends

Table 140. Atypical Antipsychotic Drugs Market Drivers

Table 141. Atypical Antipsychotic Drugs Market Challenges

Table 142. Atypical Antipsychotic Drugs Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Atypical Antipsychotic Drugs

Figure 2. Global Atypical Antipsychotic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Atypical Antipsychotic Drugs Market Share by Type in 2023 & 2030

Figure 4. Risperidone Product Picture

Figure 5. Olanzapine Product Picture

Figure 6. Quetiapine Product Picture

Figure 7. Ziprasidone Product Picture

Figure 8. Others Product Picture

Figure 9. Global Atypical Antipsychotic Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Atypical Antipsychotic Drugs Market Share by Application in 2023 & 2030

Figure 11. Bipolar I Disorder

Figure 12. Schizophrenia

Figure 13. Schizoaffective Disorder

Figure 14. Major Depressive Disorder (MDD)

Figure 15. Global Atypical Antipsychotic Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Atypical Antipsychotic Drugs Market Size (2019-2030) & (US$ Million)

Figure 17. Global Atypical Antipsychotic Drugs Sales (2019-2030) & (Units)

Figure 18. Global Atypical Antipsychotic Drugs Average Price (USD/Unit) & (2019-2030)

Figure 19. Atypical Antipsychotic Drugs Report Years Considered

Figure 20. Atypical Antipsychotic Drugs Sales Share by Manufacturers in 2023

Figure 21. Global Atypical Antipsychotic Drugs Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest Atypical Antipsychotic Drugs Players: Market Share by Revenue in 2023

Figure 23. Atypical Antipsychotic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global Atypical Antipsychotic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America Atypical Antipsychotic Drugs Sales Market Share by Country (2019-2030)

Figure 26. North America Atypical Antipsychotic Drugs Revenue Market Share by Country (2019-2030)

Figure 27. U.S. Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe Atypical Antipsychotic Drugs Sales Market Share by Country (2019-2030)

Figure 30. Europe Atypical Antipsychotic Drugs Revenue Market Share by Country (2019-2030)

Figure 31. Germany Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific Atypical Antipsychotic Drugs Revenue Market Share by Region (2019-2030)

Figure 38. China Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Taiwan Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Indonesia Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Thailand Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Malaysia Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Philippines Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Latin America Atypical Antipsychotic Drugs Sales Market Share by Country (2019-2030)

Figure 49. Latin America Atypical Antipsychotic Drugs Revenue Market Share by Country (2019-2030)

Figure 50. Mexico Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Brazil Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Argentina Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Middle East & Africa Atypical Antipsychotic Drugs Sales Market Share by Country (2019-2030)

Figure 54. Middle East & Africa Atypical Antipsychotic Drugs Revenue Market Share by Country (2019-2030)

Figure 55. Turkey Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Saudi Arabia Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. U.A.E Atypical Antipsychotic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. Global Sales Market Share of Atypical Antipsychotic Drugs by Type (2019-2030)

Figure 59. Global Revenue Market Share of Atypical Antipsychotic Drugs by Type (2019-2030)

Figure 60. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Type (2019-2030)

Figure 61. Global Sales Market Share of Atypical Antipsychotic Drugs by Application (2019-2030)

Figure 62. Global Revenue Market Share of Atypical Antipsychotic Drugs by Application (2019-2030)

Figure 63. Global Atypical Antipsychotic Drugs Price (USD/Unit) by Application (2019-2030)

Figure 64. Atypical Antipsychotic Drugs Value Chain

Figure 65. Atypical Antipsychotic Drugs Production Process

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Distributors Profiles

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions